Taiwan DCB, PITDC, TMU and US Insilico Medicine Join Forces to Develop Groundbreaking Research in applied A.I. for biomedical science

DCB, PITDC, TMU and Insilico Medicine signed a Letter of Intent (LoI) for Cooperation

The Development Center for Biotechnology (DCB), the Medical and Pharmaceutical Industrial Technology Development Center (PITDC), and Taipei Medical University (TMU), three of Taiwan’s premier biomedical institutions, have teamed up with Baltimore-based Insilico Medicine to develop groundbreaking research in applied A.I. for biomedical science. The four parties signed a Letter of Intent (LoI) for Cooperation at the BioTaiwan 2017 BioBusiness Asia Conference.

Dr. Eugene Lin, Science and Technology Advisor of the Department of Industrial Development (DoIT), Ministry of Economic Affairs (MOEA) attended the signing ceremony to recognize the significance of such cooperation. “Taiwan is world renowned for its successful ICT industry, and now the government is turning its sights towards the biomedical industry. We encourage Taiwan’s research institutes and biomedical industry to work with the best partners in the world to foster innovation,” said Dr. Lin.    

Dr. Lawrence Gan, President of DCB and a veteran of the biotech industry, noted that “A.I. has already become a force for disruptive innovation in the biomedical sciences. Since DCB’s core mission is to facilitate the growth of Taiwan’s biomedical industry, we must take a leading role in harnessing the power of A.I. in this field.”    

TMU, one of the world’s top medical schools and hospital groups, has been a pioneer in adopting state-of-the-art technologies to provide healthcare services, and recently announced the adoption of IBM’s Watson Health. “TMU is dedicated to working with global tech leaders to provide the highest quality services and research in healthcare,” said Professor Yun Yen, President of TMU.

PITDC, Taiwan’s leading medical and pharmaceutical research institute also announced its intent to adopt A.I. for drug discovery and development. “With increasing global competition, Taiwan’s pharmaceutical companies have to adopt an approach of open collaboration and take advantage of data science in order to transform and meet the needs of a fast changing future,” said Hsiu-Kang Chang, chairman of PITDC.

Insilico Medicine, a rising star in…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *